Navigation Links
Helix BioPharma Corp. announces fiscal 2007 results
Date:10/26/2007

WKN: 918 846

AURORA, ON, Oct. 26 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the year ended July 31, 2007.

During the 2007 fiscal year, the Company continued to make progress with its clinical (Topical Interferon Alpha-2b) and pre-clinical (L-DOS47) development programs. The following are selected highlights during the 2007 fiscal year and subsequent to year-end.

HIGHLIGHTS

- Topical Interferon Alpha-2b

- Announced positive Phase II clinical results with Topical

Interferon Alpha-2b in patients with HPV-induced low-grade

squamous intraepithelial lesions ("LSIL")

- Initiated enrollment in Phase II clinical trial with Topical

Interferon Alpha-2b in patients with HPV-induced ano-genital warts

- L-DOS47

- Awarded two U.S. patents for DOS47, a broad anti-cancer

therapeutic candidate

- Presented L-DOS47 findings at the fourth international conference

on "Tumour Microenvironment" in Florence, Italy

- Presented L-DOS47 findings at Keystone Symposia meeting,

"Antibodies as Drugs: From Basic Biology to Clinic"

- Signed L-DOS47 manufacturing agreement with BioVectra DCL

- Financing

- Completed a private placement financing on October 11, 2006 for

gross proceeds of $7,044,500.

- Other

- Shareholders approved management proposals and elected

management's slate of directors at the 2007 annual meeting of

shareholders, following a proxy dispute

- Announced University of Arizona Professor, Kenneth D. Hatch,M.D.,

as medical advisor

- Mr. Jerome F. McElroy resigned as Chairman and Director of the

Company

- Introduced a new company logo as part of our ongoing efforts to<
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Metavante Corp. will continue M&A activity
2. Lucigen Corp. enters global licensing agreement
3. CIO Leadership Series: Jane Durment, Marcus Corp.
4. Brady Corp. acquires Korean counterpart
5. Brady Corp. raises $137 million in public offering
6. Symphony Corp. and CareEvolution to partner
7. RedPrairie Corp. introduces new supply chain software
8. California investors acquire RedPrairie Corp.
9. Symphony Corp. moving into Fitchburg Technology Campus
10. Local group building Dane County economic development corp.
11. M & Is Metavante completes Brasfield Corp. acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... PAT and QbD remains a field that still lacks ... Pharma IQ across the PAT and QbD community it was  found ... not implementing PAT/QbD was due to a lack of personnel with ... opens its doors to industry specialists from the PAT and QbD ...
... Germany, October 11, 2011 joimax® opened ... patronage of the German Academy for Neurosurgery (GANS) and ... Neurosurgery at the "Städtisches Klinikum" in Karlsruhe, Prof. Dr. ... place in Karlsruhe, South Germany, October 5 to 8. ...
... Oct. 11, 2011 STAAR Surgical Company (NASDAQ: STAA ) ... quarter ended September 30, 2011 on Monday, October 24, 2011 ... will host a conference call on Monday, October 24, 2011 ... to discuss the Company,s third quarter results and recent corporate ...
Cached Biology Technology:Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 3STAAR Surgical Announces Third Quarter 2011 Results Release Date and Conference Call 2
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Dec. 17, 2012 The University of Houston (UH) ... thanks to a computer hardware donation from Total, a ... nodes that will occupy four racks of space. ... computing resources," said Jaspal Subhlok, chairman of UH,s department ...
... December 2012)New research released today, on the eve of an ... agencies and investors for a growing spate of violent clashes ... of resources from the rural poor to investors is underway, ... Top global experts at the meeting noted as well that ...
... up on snack foods may increase cancer risk in ... cancers. Published early online in CANCER , a ... suggests that an eating pattern low in snack foods ... syndromelower their risk. Lynch syndrome is an inherited ...
Cached Biology News:Total donates high-speed computer cluster to UH 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 3New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 4Snack attack: Eating unhealthy snack foods may affect cancer risk in patients with Lynch syndrome 2
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: